Inventor · disambiguated record
David Schaer
Also filed as: SCHAER DAVID · SCHAER DAVID ARLEN · SCHAER DAVID R
27 granted patents·18 pending applications·128 citations·filing 2003–2025
96Inventor score
Top patents by PatentIndex Score
45 records- 0197US10912831B1Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted Feb 9, 2021·6 cites·26 claims
- 0297US10836830B2Antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted Nov 17, 2020·12 cites·45 claims
- 0396US11638755B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted May 2, 2023·4 cites·20 claims
- 0496US10626181B2Nucleic acids encoding anti-OX40 antibodiesAGENUS INC·Filed 2019·Granted Apr 21, 2020·7 cites·35 claims
- 0596US10280226B2Anti-GITR antibodies and methods of use thereofAGENUS INC·Filed 2018·Granted May 7, 2019·17 cites·30 claims
- 0696US10155818B2Anti-GITR antibodies and methods of use thereofAGENUS INC·Filed 2015·Granted Dec 18, 2018·17 cites·4 claims
- 0795US10259882B2Anti-OX40 antibodiesAGENUS INC·Filed 2016·Granted Apr 16, 2019·16 cites·47 claims
- 0894US10144779B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2016·Granted Dec 4, 2018·12 cites·92 claims
- 0993US11013802B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2017·Granted May 25, 2021·5 cites·21 claims
- 1092US11267889B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted Mar 8, 2022·2 cites·26 claims
- 1192US10479833B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2018·Granted Nov 19, 2019·8 cites·34 claims
- 1289US11345755B2Anti-PD-1 antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted May 31, 2022·2 cites·25 claims
- 1388US10800849B2Anti-GITR antibodies and methods of use thereofAGENUS INC·Filed 2018·Granted Oct 13, 2020·2 cites·26 claims
- 1487US10577426B2Anti-GITR antibodies and methods of use thereofAGENUS INC·Filed 2018·Granted Mar 3, 2020·3 cites·21 claims
- 1586US10323091B2Anti-PD-1 antibodies and methods of use thereofAGENUS INC·Filed 2016·Granted Jun 18, 2019·5 cites·94 claims
- 1685US12246066B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2023·Granted Mar 11, 2025·0 cites·19 claims
- 1785US11472883B2Methods of administering anti-OX40 antibodiesAGENUS INC·Filed 2020·Granted Oct 18, 2022·1 cites·15 claims
- 1885US11332536B2Vectors comprising nucleic acids encoding anti-OX40 antibodiesAGENUS INC·Filed 2020·Granted May 17, 2022·1 cites·22 claims
- 1984US11993653B2Antibodies and methods of use thereofAGENUS INC·Filed 2019·Granted May 28, 2024·2 cites·19 claims
- 2084US11447557B2Antibodies and methods of use thereofAGENUS INC·Filed 2016·Granted Sep 20, 2022·3 cites·46 claims
- 2184US11136404B2Anti-OX40 antibodiesAGENUS INC·Filed 2019·Granted Oct 5, 2021·1 cites·64 claims
- 2284US10829559B2Anti-GITR antibodies and methods of use thereofAGENUS INC·Filed 2019·Granted Nov 10, 2020·1 cites·8 claims
- 2384US2023167186A1Methods of administering anti-ox40 antibodiesAGENUS INC·Filed 2022·Application pending·0 cites
- 2484US2023108348A1Methods of administering anti-ox40 antibodiesAGENUS INC·Filed 2022·Application pending·0 cites
- 2582US2023039577A1Anti-gitr antibodies and methods of use thereofAGENUS INC·Filed 2022·Application pending·0 cites
- 2680US11359028B2Anti-OX40 antibodies and anti-GITR antibodiesAGENUS INC·Filed 2019·Granted Jun 14, 2022·1 cites·16 claims
- 2780US2023406946A1Antibodies and methods of use thereofAGENUS INC·Filed 2022·Application pending·0 cites
- 2880US2023399413A1Antibodies and methods of use thereofAGENUS INC·Filed 2022·Application pending·0 cites
- 2979US12492257B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2022·Granted Dec 9, 2025·0 cites·20 claims
- 3079US2022098316A1Anti-ox40 antibodies and methods of use thereofAGENUS INC·Filed 2021·Application pending·0 cites
- 3176US2022372149A1Anti-pd-1 antibodies and methods of use thereofAGENUS INC·Filed 2022·Application pending·0 cites
- 3275US11897962B2Anti-GITR antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted Feb 13, 2024·0 cites·11 claims
- 3375US2025360209A1Anti-ctla-4 antibodies and methods of use thereofAGENUS INC·Filed 2025·Application pending·0 cites
- 3473US11401335B2Anti-GITR antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted Aug 2, 2022·0 cites·16 claims
- 3573US2022389107A1Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereofAGENUS INC·Filed 2022·Application pending·0 cites
- 3673US2022380479A1Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereofAGENUS INC·Filed 2022·Application pending·0 cites
- 3772US2021171648A1Antibodies and methods of use thereofAGENUS INC·Filed 2020·Application pending·0 cites
- 3867US2021324097A1Anti-ox40 antibodies and methods of use thereofAGENUS INC·Filed 2021·Application pending·0 cites
- 3966US10450373B2Anti-PD-1 antibodies and methods of use thereofAGENUS INC·Filed 2019·Granted Oct 22, 2019·0 cites·30 claims
- 4055US2020079862A1Anti-ox40 antibodies and methods of use thereofAGENUS INC·Filed 2016·Application pending·0 cites
- 4145US2004077271A1Apparatus and method for converting a compact disc into a spinning toy topFiled 2003·Application pending·0 cites
- 4242US2019269666A1Combination therapy with merestinib and anti-pd-l1 or anti-pd-1 inhibitors for use in the treatment of cancerLILLY CO ELI·Filed 2017·Application pending·0 cites
- 4341US2018291107A1Combination therapy for cancerLILLY CO ELI·Filed 2016·Application pending·0 cites
- 4441US2020123265A1Anti-gitr antibodies and methods of use thereofAGENUS INC·Filed 2016·Application pending·0 cites
- 4536US2019160148A1Combination of pembrolizumab and abemaciclib for the treatment of cancerLILLY CO ELI·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when David Schaer files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →